

# CITATION REPORT

List of articles citing

## Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analy

DOI: 10.1007/s10620-016-4044-2  
Digestive Diseases and Sciences, 2016, 61, 2108-17.

**Source:** <https://exaly.com/paper-pdf/65541978/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
62	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?. <i>Diabetologia</i> , <b>2016</b> , 59, 1145-7	10.3	11
61	Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 1790-2	4	1
60	Is screening for NASH in type 2 DM cost effective?. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2016</b> , 746, 24-24	0.1	
59	Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 1211-3	13.4	20
58	Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. <i>Drug Metabolism Reviews</i> , <b>2017</b> , 49, 197-211	7	210
57	Obesity and Nonalcoholic Fatty Liver Disease. <b>2018</b> , 89-97		1
56	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología</i> , <b>2018</b> , 41, 328-349	0.9	30
55	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 99-114	15.2	170
54	Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. <i>Diabetologia</i> , <b>2018</b> , 61, 1306-1314	10.3	14
53	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. <i>Hepatology</i> , <b>2018</b> , 67, 328-357	11.2	2641
52	Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). <i>Clinical and Experimental Hepatology</i> , <b>2018</b> , 4, 153-157	2.2	6
51	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2018</b> , 41, 328-349	0.1	1
50	Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition. <i>Hepatology</i> , <b>2018</b> , 68, 2405-2412	11.2	25
49	Non-alcoholic fatty liver disease and the interface between primary and secondary care. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 509-517	18.8	64
48	Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study. <i>Journal of General Internal Medicine</i> , <b>2019</b> , 34, 2772-2778	4	25
47	Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 4574-4586	3.3	44
46	A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). <i>Advances in Therapy</i> , <b>2019</b> , 36, 1574-1594	4.1	38

45	Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	27
44	Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 948-963	15.1	135
43	Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. <i>Current Hepatology Reports</i> , <b>2019</b> , 18, 444-454	1	1
42	Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 296-307	6.1	10
41	Clinical workup of fatty liver for the primary care provider. <i>Postgraduate Medicine</i> , <b>2019</b> , 131, 19-30	3.7	2
40	Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. <i>Pharmacoeconomics</i> , <b>2020</b> , 38, 485-497	4.4	5
39	Readiness for the epidemic: The adult nonalcoholic fatty liver disease toolkit for primary care nurse practitioners. <i>Journal of the American Association of Nurse Practitioners</i> , <b>2020</b> , 32, 323-331	1	3
38	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	5
37	Non-Alcoholic Fatty Liver Disease. <b>2020</b> ,		1
36	An Algorithmic Approach to NAFLD Screening: From PCP to Specialist. <i>ACG Case Reports Journal</i> , <b>2020</b> , 7, e00473	0.6	0
35	Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. <i>Gastroenterology</i> , <b>2020</b> , 159, 1985-1987.e4	13.3	34
34	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2020</b> , 30, 1014-1022	4.5	4
33	Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 513-526	6.1	23
32	Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211042200	4.7	0
31	Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 615	3.2	2
30	Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease.. <i>Journal of Clinical and Experimental Hepatology</i> , <b>2022</b> , 12, 362-371	4.1	
29	Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107978	3.2	1
28	Screening for nonalcoholic fatty liver disease-when, who and how?. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 5803-5821	5.6	1

27	Determining the Target Population That Would Most Benefit from Screening for Hepatic Fibrosis in a Primary Care Setting. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	0
26	Work up of fatty liver by primary care physicians, review. <i>Annals of Medicine and Surgery</i> , <b>2020</b> , 50, 41-48		1
25	Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. <i>Journal of Clinical Gastroenterology</i> , <b>2021</b> , 55, 891-902	3	8
24	Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 3929-3940	5.6	20
23	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. <i>Endocrinology and Metabolism</i> , <b>2020</b> , 35, 243-259	3.5	5
22	Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. <i>Diabetes and Metabolism Journal</i> , <b>2020</b> , 44, 382-401	5	16
21	The diagnostic conundrum in non-alcoholic fatty liver disease. <i>Exploration of Medicine</i> , <b>2020</b> , 1,	1.1	1
20	Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease-A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	1
19	Diagnostic Algorithm for the Identification of NAFLD in Primary Care. <b>2020</b> , 225-234		
18	Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic. <i>Gastroenterology and Hepatology</i> , <b>2019</b> , 15, 357-365	0.7	8
17	An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care.. <i>Diabetic Medicine</i> , <b>2022</b> , e14799	3.5	2
16	Accuracy of Non-invasive Indices for Diagnosing Hepatic Steatosis Compared to Imaging in a Real-World Cohort.. <i>Digestive Diseases and Sciences</i> , <b>2022</b> , 1	4	0
15	Non-alcoholic fatty liver disease: a multidisciplinary clinical practice approach—the institutional adaptation to existing Clinical Practice Guidelines. <b>2022</b> , 2, 12-22		1
14	Patients with type 2 diabetes and elevated fibrosis-4 are under-referred to hepatology and have unrecognized hepatic decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> ,	4	0
13	When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 3286	5.1	0
12	AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. <i>Gastroenterology</i> , <b>2022</b> ,	13.3	6
11	Prevalence of Hepatic Steatosis in Adults Presenting to the Emergency Department Identified by Unenhanced Chest CT. <b>2022</b> ,		
10	Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes.		0

9	NAFLD as the metabolic hallmark of obesity.	0
8	Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. <b>2022</b> , 9, 419	1
7	Screening strategy for nonalcoholic fatty liver disease.	0
6	Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. <b>2022</b> , 21,	3
5	Prognostic value of liver fibrosis assessed by the FIB-4 index in patients with acute coronary syndrome. <b>2023</b> ,	0
4	AI-based opportunistic CT screening of incidental cardiovascular disease, osteoporosis, and sarcopenia: cost-effectiveness analysis.	0
3	Valor pronóstico de la fibrosis hepática valorada por el índice FIB4 en pacientes ingresados por síndrome coronario agudo. <b>2023</b> ,	0
2	ABDA score: a non-invasive model to identify subjects with fibrotic non-alcoholic steatohepatitis in the community. <b>2023</b> ,	0
1	Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis. <b>2023</b> , 77, 1702-1711	0